Traders should focus on the upcoming Q4 2026 data readout for zolucatetide in desmoid tumors and the FDA alignment meeting for the Phase 3 trial design. The $1.1B cash runway removes near-term financing risk, making the stock a pure play on pipeline execution. Monitor for any safety signals or competitive developments in the Wnt/beta-catenin space.
Price Chart
Executive Summary
Parabilis Medicines reported Q2 2026 results, highlighting a net loss of $52.5M vs $34.8M a year ago, driven by increased R&D and G&A spending. The company ended the quarter with $1.1B in cash following a $770.5M IPO and a $125M Regeneron collaboration. Key catalysts include maturing Phase 1/2 data for zolucatetide in desmoid tumors in Q4 2026 and a planned Phase 3 registrational trial initiation in 1H 2027. The strong cash position and pipeline progress are positive, but the clinical-stage nature and widening losses temper the outlook.
Key Financial Metrics
Key Facts
- Net loss of $52.5M for Q2 2026, compared to $34.8M in Q2 2025.
- Cash, cash equivalents, and marketable securities of $1.1B as of June 30, 2026, expected to fund operations into 2030.
- Completed upsized IPO raising $770.5M and a $125M strategic collaboration with Regeneron.
- Lead candidate zolucatetide showing 74% ORR and 100% DCR in desmoid tumors; Phase 3 registrational trial on track for 1H 2027.
- R&D expenses were $39.4M for Q2 2026, up from $30.1M in Q2 2025.
Financial Impact
Net loss increased by $17.7M YoY to $52.5M; cash position strengthened by $1.06B from $27.7M at year-end 2025 to $1.1B.
Risk Factors
- Clinical-stage biotech with no approved products; zolucatetide may fail in Phase 3 trials.
- Widening net losses and increasing operating expenses as the company scales.
- Dependence on successful execution of the Regeneron collaboration and pipeline milestones.
- Competition from other therapies targeting desmoid tumors and Wnt-driven cancers.
Market Snapshot
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-347869 |
| Document: ck0001657677-20260813.htm | 0001193125-26-347869 |
| Document: ck0001657677-ex99_2.htm | 0001193125-26-347869 |
| Document: 0001193125-26-347869-index-headers.html | 0001193125-26-347869 |
| Document: 0001193125-26-347869-index.html | 0001193125-26-347869 |
| Document: 0001193125-26-347869.txt | 0001193125-26-347869 |
| 8-K Data (Synthetic) | 0001193125-26-347869 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 24, 2026 3d ago | Press Release | $24.79 | awaiting T+60 | — | $26.69 (+7.66%) |
Oct 19, 2026 8d ago | Press Release | $25.35 | awaiting T+60 | — | $26.69 (+5.28%) |
Sep 15, 2026 5w ago | 8-K | $36.88 | awaiting T+60 | — | $26.69 (−27.64%) |
Sep 2, 2026 7w ago | 8-K | $40.75 | awaiting T+60 | — | $26.69 (−34.51%) |
Aug 13, 2026 10w ago | 8-K | $35.67 | awaiting T+60 | — | $26.69 (−25.18%) |
Aug 13, 2026 10w ago | Press Release | $35.67 | awaiting T+60 | — | $26.69 (−25.18%) |
Jul 22, 2026 13w ago | Insider Buy | $32.81 $22.75 | ▼ −30.66% | ▼ −34.31% | $26.69 (−18.66%) |
Jun 29, 2026 17w ago | Insider Cluster | $29.19 $33.31 | ▲ +14.11% | ▲ +10.50% | $26.69 (−8.57%) |
Jun 16, 2026 18w ago | Insider Cluster | $26.03 $36.16 | ▲ +38.92% | ▲ +36.23% | $26.69 (+2.53%) |
Jun 15, 2026 19w ago | Insider Cluster | $26.59 $36.88 | ▲ +38.70% | ▲ +36.84% | $26.69 (+0.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers